We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
U.K. recommends ranibizumab as a cost-effective treatment for wet AMD.
- Authors
Cimberle, Michela
- Abstract
This article announces a decision on coverage of ranibizumab by the British National Institute for Health and Clinical Excellence (NICE). The decision enables patients with wet age-related macular degeneration to receive treatment from the National Health Service (NHS). Particular focus is given to the average cost of anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab, along with the wet AMD epidemiology accepted by NICE each year. The Royal College of Ophthalmologists played a role in the effort to make anti-VEGF therapy accessible.
- Subjects
UNITED Kingdom; NATIONAL Institute for Health &; Care Excellence (Great Britain); AGE factors in retinal degeneration; GREAT Britain. National Health Service; VASCULAR endothelial growth factors
- Publication
Ocular Surgery News, 2009, Vol 27, Issue 2, p42
- ISSN
8750-3085
- Publication type
Article